GSK has had a mixed performance in the stock market in recent times, registering both highs and lows. The company has been affected by several factors ranging from
regulatory decisions to
litigation affairs and
bold business moves. For instance, the stock dropped following underwhelming results and disappointing sales of top two vaccines. On the other hand, the shares dramatically jumped following the announcement of a $2.2 billion
Zantac settlement. This settlement resulted from thousands of lawsuits tied to the Zantac drug produced by the company. GSK is also in the talks to acquire American bio-tech IDRx, a deal that could reach up to
$1 billion. The company's shares also fell after a sharp decline in demand for RSV and shingles vaccines, leading to lower projected sales in 2024. Despite mixed results, GSK remains one of the top FTSE dividend stocks, providing a steady stream of income for long-term investors. Finally, the vaccine stocks were further affected by the nomination of Robert Kennedy Jr. On a positive note, GSK's cancer drug recently received FDA's breakthrough designation.
GSK Stocks News Analytics from Wed, 01 May 2024 07:00:00 GMT to Fri, 10 Jan 2025 13:10:00 GMT -
Rating 0
- Innovation 6
- Information 7
- Rumor 4
